Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Summary
The bill tells the Center for Medicare and Medicaid Innovation to test a pricing model where manufacturers must provide the "most‑favored‑nation" price – the second‑lowest price they charge in a list of reference countries – for covered drugs to eligible Medicaid and Medicare patients. It applies to drugs sold abroad in at least two of those countries and requires manufacturers to report pricing data. The goal is to lower prescription costs for beneficiaries while encouraging manufacturers to negotiate better prices.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when HR 7837 changes status, plus AI-powered summaries and stage predictions.
Sign up free